-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OvLEeKOppq4uXGbdh171+cBMrSCp3TTw09OnfW4YxD3GLFaFFg401vJGxMvbaf6W XtiZF67BSsHg/I3VIrPyHw== 0000950109-97-006151.txt : 19971001 0000950109-97-006151.hdr.sgml : 19971001 ACCESSION NUMBER: 0000950109-97-006151 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19970930 SROS: NASD SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: THERAPEUTIC DISCOVERY CORP CENTRAL INDEX KEY: 0000899753 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943173191 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-45501 FILM NUMBER: 97688504 BUSINESS ADDRESS: STREET 1: 1454 PAGE MILL RD STREET 2: P O BOX 10051 CITY: PALO ALTO STATE: CA ZIP: 94303 BUSINESS PHONE: 6504968200 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ALZA CORP CENTRAL INDEX KEY: 0000004310 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770142070 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 950 PAGE MILL RD STREET 2: PO BOX 10950 CITY: PALO ALTO STATE: CA ZIP: 94303-0802 BUSINESS PHONE: 4154945000 MAIL ADDRESS: STREET 1: 950 PAGE MILL RD STREET 2: PO BOX 10950 CITY: PALO ALTO STATE: CA ZIP: 94303 SC 13D/A 1 AMENDMENT #2 - -------------------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 -------------------------------- SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Therapeutic Discovery Corporation --------------------------------- (Name of Issuer) Class A Common Stock, Par Value $0.01 ------------------------------------- (Title of Class of Securities) 883376105 --------- CUSIP Number Peter D. Staple, Esq. ALZA Corporation 950 Page Mill Road Palo Alto, California 94303 (650) 494-5000 With a copy to: Sarah A. O'Dowd, Esq. Heller, Ehrman, White & McAuliffe 525 University Avenue Palo Alto, California 94301 (650) 324-7000 ------------------------------------------------------ (Name, address and telephone number of person authorized to receive notices and communications) September 29, 1997 ---------------------------------------------- (Date of Event which requires filing of this statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box: [_] 2 CUSIP No. 883376105 1) Name of Reporting Persons: S.S. or I.R.S Identification No. of above person ALZA Corporation I.R.S. Identification No. 77-0142070 - -------------------------------------------------------------------------------- 2) Check the Appropriate Box if a Member of a Group (a) [_] ------------------------------------------------------------------ (b) [_] ------------------------------------------------------------------ - -------------------------------------------------------------------------------- 3) SEC Use Only -------------------------------------------------------------- - -------------------------------------------------------------------------------- 4) Source of Funds: 00 - -------------------------------------------------------------------------------- 5) [_] Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) - -------------------------------------------------------------------------------- 6) Citizenship or Place of Organization: Delaware - -------------------------------------------------------------------------------- 7) Sole Voting Power 7,734,424 Shares of Class A Common Stock and 100 Shares of Class B Common Stock ----------------------------------------------------------- Number of Shares 8) Shared Voting Power Beneficially None Owned by Each ----------------------------------------------------------- Reporting Person With 9) Sole Dispositive Power 7,734,424 Shares of Class A Common Stock and 100 Shares of Class B Common Stock ----------------------------------------------------------- 10) Shared Dispositive Power None ----------------------------------------------------------- 11) Aggregate Amount Beneficially Owned by Each Reporting Person: 7,734,424 Shares of Class A Common Stock and 100 Shares of Class B Common Stock - -------------------------------------------------------------------------------- 12) [_] Check if the Aggregate Amount in Row (11) Excludes Certain Shares - -------------------------------------------------------------------------------- 13) Percent of Class Represented by amount in Row (11): 100.0% (See response to Item 3) - -------------------------------------------------------------------------------- 14) Type of Reporting Person CO - -------------------------------------------------------------------------------- Item 1. Security and Issuer. ------------------- This statement constitutes Amendment No. 2 to the Statement on Schedule 13D, dated June 22, 1993, relating to shares of Class A Common Stock, $.01 par value per share (the "Class A Common Stock") of Therapeutic Discovery Corporation, a Delaware corporation ("TDC"). The reporting person, ALZA Corporation, a Delaware corporation, ("ALZA") is filing this Amendment No. 2 on Schedule 13D because, on September 29, 1997 it concluded the exercise of its option to purchase all of the issued and outstanding Class A Common Stock of TDC. As a consequence, ALZA now owns all issued and outstanding stock of TDC and TDC is a wholly owned subsidiary of ALZA. 3 Item 5. Interest in Securities of the Issuer. ------------------------------------ As of September 29, 1997, ALZA owns 7,734,424 shares of Class A Common Stock and 100 shares of Class B Common Stock of TDC. ALZA owns 100% of the issued and outstanding stock of TDC. 4 Item 7. Exhibits. -------- None. SIGNATURE After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. September 30, 1997 ALZA CORPORATION By: /s/ PETER D. STAPLE ------------------------------- Peter D. Staple Senior Vice President and General Counsel 5 -----END PRIVACY-ENHANCED MESSAGE-----